Alithea Genomics
PrivateLast Round
Seed
Mar 4, 2026
Total Funding Raised
$13.91M
Momentum
Top 25%
of companies Caplight tracks
Company Overview
Alithea Genomics is a biotechnology company that develops and commercializes massively multiplexed library preparation solutions for RNA sequencing, designed to accelerate drug development and biomarker discovery.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery, Biotech Equipment, Precision Medicine
Business Model
B2B
Customer Profile
Services & Consulting, Hardware Sales
AI Layer
Infrastructure
Keywords
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Alithea Genomics Comparables
Compare Alithea Genomics with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Lexogen | 86% | |
| BioSpyder Technologies, Inc. | 85% | |
| BioClavis | 78% |
Alithea Genomics Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Seed | Mar 4, 2026 | ||||
| Debt | Sep 24, 2024 | ||||
| Seed | Mar 14, 2024 | ||||
| Debt | Mar 21, 2023 | ||||
| Seed | May 24, 2022 | ||||
Grant | Apr 28, 2021 |
Key People
Founding team and executive leadership
Alithea Genomics Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| TechU Ventures | Seed |
| Foundation for Technological Innovation | Debt |
| Novalis Biotech | Seed |
| Venture Kick | Grant |
| Zurcher Kantonalbank | Seed |
Market signals
Structured signals derived from secondary market and firmographic data.
- Mar 4, 2026
$9M round with participation from Novalis Biotech.
- Oct 8, 2025
Launched MERCURIUS Spheroid DRUG-seq for 3D drug screening.
Recent news
Latest coverage and updates
- launchesJun 22, 2026
Alithea Genomics launched early access program for MERCURIUS 1536 DRUG-seq on Jun 16th '26.
Alithea Genomics Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Request accessFrequently Asked Questions
Common questions about Alithea Genomics's valuation, stock price, and market status.
Is Alithea Genomics a public or private company?
Alithea Genomics is a private company.
What is the current stock price of Alithea Genomics?
Alithea Genomics is a private company with no public stock price. No recent secondary market data is available.
How much is Alithea Genomics worth (valuation)?
Valuation information for Alithea Genomics is not publicly available.
Can I buy Alithea Genomics stock?
Alithea Genomics shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors. Visit https://www.caplight.com to learn more.
When was Alithea Genomics's last funding round?
Alithea Genomics's most recent funding round was Seed on March 4, 2026.
Who are the main investors in Alithea Genomics?
Key investors in Alithea Genomics include Novalis Biotech.
Will Alithea Genomics IPO soon?
No public IPO plans have been announced for Alithea Genomics.
How can I track Alithea Genomics secondary market activity?
Caplight tracks bids, offers, and trades for private companies. Visit https://www.caplight.com to monitor Alithea Genomics's secondary market activity and sign up for updates.